Contraceptive vaginal ring.
The vaginal contraceptive ring is comprised of ethinyl vinyl acetate that releases ethinyl estradiol and the third-generation progestin, etonorgestrel. It was approved by the Food and Drug Administration in 2001. The vaginal contraceptive ring is highly efficacious with a Pearl Index of 1.18 and an efficacy of 99.1%. Effectiveness is similar with actual use.
Madden
Tessa
T
Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. maddent@wustl.edu
Blumenthal
Paul
P
D003271:Contraceptive Agents, Female / Q000493:pharmacokinetics* / Q000494:pharmacology*; D003274:Contraceptive Devices, Female / Q000009:adverse effects* / Q000592:standards* / Q000706:statistics & numerical data; D017135:Desogestrel / Q000493:pharmacokinetics / Q000494:pharmacology; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000493:pharmacokinetics / Q000494:pharmacology; D005260:Female; D006801:Humans; D010060:Ovulation / Q000187:drug effects*; D010349:Patient Compliance; D017060:Patient Satisfaction; D016896:Treatment Outcome
D003271:Contraceptive Agents, Female; D004338:Drug Combinations; C044815:etonogestrel; D004997:Ethinyl Estradiol; D017135:Desogestrel